DR4, referred to as TRAIL Receptor-1, is a novel death domain containing receptor whose ligand has been identified as TRAIL or apoptosis-inducing ligand 2 (Apo2L). It is a member of the TNF superfamily of receptors that induce apoptosis. It is expressed in most human tissues including spleen, peripheral blood leukocytes, small intestine, and thymus.
Immunogène
synthetic peptide corresponding to amino acids 1-20 of the N-terminal of the mature human DR4.
Application
Anti-DR4 antibody produced in rabbit is suitable for microarray and immunoblotting at a working dilution of 1:500-1:1000 using total HeLa, K562, and Jurkat whole cell lysates. It was used as a primary antibody in the immunodetection of DR4 in cell lysate of human small cell lung carcinoma cells. It was used as a primary antibody in the immunoblot analysis of fetal and adenocarcinoma epithelial colon cells in a study.
Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below. Western Blotting (1 paper)
Actions biochimiques/physiologiques
DR4 induces apoptosis in a variety of human tumor cell lines, but not in normal cells and activates NF-κB.
Forme physique
Solution in phosphate buffered saline containing 0.02% sodium azide
Clause de non-responsabilité
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Vous ne trouvez pas le bon produit ?
Essayez notre Outil de sélection de produits.
Code de la classe de stockage
10 - Combustible liquids
Faites votre choix parmi les versions les plus récentes :
The resistance of transformed epithelial cells to a detachment-induced apoptosis (anoikis) can significantly affect their susceptibility to anticancer therapy. We showed that detachment of both fetal (FHC) and adenocarcinoma (HT-29) human colon epithelial cells resulted in the activation of the
TRAIL is considered as a promising anti-cancer agent, because of its ability to induce apoptosis in cancer but not in most normal cells. However, growing evidence exist that many cancer cells are resistant to its apoptotic effects. SCLC is a
The Journal of biological chemistry, 271(22), 12687-12690 (1996-05-31)
Cytokines in the tumor necrosis factor (TNF) family regulate development and function of the immune system. We have isolated a new member of this family, designated Apo-2 ligand (Apo-2L), via an expressed sequence tag. Apo-2L is a 281-amino acid protein
Science (New York, N.Y.), 276(5309), 111-113 (1997-04-04)
TRAIL (also known as Apo-2L) is a member of the tumor necrosis factor (TNF) ligand family that rapidly induces apoptosis in a variety of transformed cell lines. The human receptor for TRAIL was found to be an undescribed member of
A novel tumor necrosis factor (TNF) family member has been cloned and characterized. This protein, designated TNF-related apoptosis-inducing ligand (TRAIL), consists of 281 and 291 aa in the human and murine forms, respectively, which share 65% aa identity. TRAIL is
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..